NCT07653100招募中3 期
A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Pfizer
- 入组人数
- 540
- 试验地点
- 25
研究概览
简要总结
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
盲法说明
Double-blinded, placebo-controlled.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants ≥18 years of age at Visit
- •Participants who are ambulatory and live independently in the community.
- •Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- •Applicable to participants 18 through 59 years of age: Participants who are healthy or have stable preexisting diseases. These participants are considered at high risk of RSV disease by having at least 1 reportable stable chronic medical condition(s) that belongs to 1 or more of the following:
- •Chronic heart disease (ie, coronary artery disease, heart failure, or congenital heart disease)
- •Chronic lung disease (ie, COPD, emphysema, asthma, interstitial lung disease, or cystic fibrosis)
- •Nongestational diabetes mellitus type 1 or type 2
- •Severe obesity (body mass index [BMI] ≥40 kg/m2)
- •Chronic liver disease (ie, cirrhosis)
- •Chronic kidney disease (not including end-stage renal disease with or without dialysis)
- •Chronic neurological disease that causes impaired airway clearance or respiratory muscle weakness (ie, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy)
- •Chronic hematologic disease (ie, sickle cell disease or thalassemia)
- •Note: A chronic medical condition for this study is defined as:
- •Duration ≥6 months.
- •Requires regular medical follow-up or ongoing prescribed medication or hospitalization in the previous year.
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.
排除标准
- •Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- •History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
- •Prior history of any subtype of Guillain-Barré syndrome of any etiology.
- •Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
- •Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- •Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study.
研究组 & 干预措施
RSVpreF
Experimental
RSVpreF Vaccine
干预措施: RSVpreF (Biological)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Biological)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
1 期
An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005NCT07442149Alumis Inc135
尚未招募
1 期
A Phase 1 Study of KHN707 Tablets in Healthy ParticipantsHealthy Adult ParticipantsNCT07557537Chengdu Kanghong Pharmaceutical Group Co., Ltd.38
招募中
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healthy Subjects.HealhtyNCT07521345Haisco Pharmaceutical Group Co., Ltd.46
招募中
1 期
A Study of B2065 in Patients With Acute Ischemic StrokeNCT07371624Tasly Pharmaceutical Group Co., Ltd54
尚未招募
2 期
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren SyndromeNCT07375524Shanghai Escugen Biotechnology Co., Ltd40